Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from OKYO Pharma Limited Sponsored ADR ( (OKYO) ).
On September 22, 2025, OKYO Pharma announced plans for a new stage in the clinical development of its lead drug candidate, urcosimod, aimed at treating neuropathic corneal pain (NCP). Following promising results from a Phase 2 trial, where 75% of patients experienced significant pain reduction, the company is advancing to a multiple-ascending-dose clinical trial involving 100 patients across several U.S. sites. This trial is part of OKYO’s strategy to define the optimal registration dose for future Phase 3 trials and further understand urcosimod’s drug characteristics. The company is also progressing towards discussions with the FDA, leveraging its Fast-Track designation to expedite the process.
The most recent analyst rating on (OKYO) stock is a Buy with a $13.00 price target. To see the full list of analyst forecasts on OKYO Pharma Limited Sponsored ADR stock, see the OKYO Stock Forecast page.
Spark’s Take on OKYO Stock
According to Spark, TipRanks’ AI Analyst, OKYO is a Underperform.
OKYO Pharma Limited’s stock is primarily affected by its significant financial challenges, including no revenue generation and negative equity. Technical analysis provides a neutral to slightly bearish outlook, while traditional valuation metrics are not applicable, reflecting typical biotech industry characteristics.
To see Spark’s full report on OKYO stock, click here.
More about OKYO Pharma Limited Sponsored ADR
OKYO Pharma Limited is a clinical stage biopharmaceutical company focused on developing innovative therapies for neuropathic corneal pain and dry eye disease. The company is listed on the NASDAQ Capital Market and is engaged in the discovery and development of novel molecules to address these ophthalmic conditions.
Average Trading Volume: 131,390
Technical Sentiment Signal: Buy
Current Market Cap: $74.47M
See more insights into OKYO stock on TipRanks’ Stock Analysis page.